Mark Johnson, MD | |
278 Franklin Rd Ste 150, Brentwood, TN 37027-3265 | |
(615) 506-0536 | |
Not Available |
Full Name | Mark Johnson |
---|---|
Gender | Male |
Speciality | General Practice |
Location | 278 Franklin Rd Ste 150, Brentwood, Tennessee |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1427528546 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208800000X | Urology | 20344 (Tennessee) | Secondary |
208D00000X | General Practice | 20344 (Tennessee) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mark Johnson, MD 278 Franklin Rd Ste 150, Brentwood, TN 37027-3265 Ph: (615) 506-0536 | Mark Johnson, MD 278 Franklin Rd Ste 150, Brentwood, TN 37027-3265 Ph: (615) 506-0536 |
News Archive
Noting this month marks the 40th anniversary of Roe v. Wade, the Supreme Court's landmark case on the issue of abortion, writer and advocate Mandy Van Deven writes in a GlobalPost commentary that the decision "provided a framework for sexual and reproductive rights used by advocates from San Francisco to Santiago, and the past year yielded significant progress on abortion rights in Latin America."
Eye research charity, Fight for Sight, is funding the development of an ‘organ-on-chip' that for the first time will be used to help investigate glaucoma, a leading cause of blindness.
An editorial by Marcus Plescia, MD, MPH, director of the Division of Cancer Prevention and Control at the Centers for Disease Control and Prevention (CDC), calls for a more organized and comprehensive approach to increase cancer screening participation among those who are insured or are likely to become insured through the Patient Protection and Affordable Care Act.
ARIAD Pharmaceuticals, Inc. today announced updated clinical data from an ongoing Phase 1 study of its investigational pan-BCR-ABL inhibitor, AP24534, in patients with resistant and refractory chronic myeloid leukemia (CML). The data confirm strong clinical evidence of hematologic, cytogenetic and molecular anti-leukemia activity of AP24534, a multi-targeted kinase inhibitor, in heavily pretreated patients with CML, including those with the T315I mutation of the target protein, BCR-ABL.
A new study found that the prevalence of metabolic health is very low among American adults, even among those who have normal weight.
› Verified 5 days ago